Contacts at the Company
Robert V. Toni, President & CEO
Benny Ward, CFO
(919) 876-7800

At The Financial Relations Board/BSMG Worldwide
Alison Zeigler - General Info
Julie Tu - Analyst Info
Judith Sylk-Siegel- Media Info
(212) 445-8000

For Immediate Release
October 16, 2001



RALEIGH, N.C., Oct. 16 -- CLOSURE Medical Corporation (Nasdaq: CLSR), a medical tissue adhesive products company, today announced that it intends to release, on Tuesday, October 23, 2001, financial results for the third quarter ended September 30, 2001 and an outlook of the Company's expectations for 2002. In conjunction with this release CLOSURE will host a conference call that will be broadcast simultaneously live over the Internet.


Individuals wishing to participate on the webcast, to be held at 4:30 PM ET on Tuesday, October 23, 2001, can access the event at . Please allow extra time prior to the call to download the streaming media software required for listening to the Internet broadcast. The online archive of the broadcast will be available within 2 hours of the live call and will be available for replay.


CLOSURE Medical Corporation, headquartered in Raleigh, North Carolina, develops, manufactures, and commercializes medical tissue adhesive products based on its proprietary cyanoacrylate technology. CLOSURE's proprietary technology has customized the physical and chemical properties of cyanoacrylates to develop medical adhesive formulations to close and seal topical skin wounds and incisions, as well as formulations to close or seal internal wounds.


Currently marketed nonabsorbable tissue adhesive products include: DERMABOND Topical Skin Adhesive, which is used to replace sutures and staples for closure of certain lacerations and incisions; SOOTHE-N-SEAL™ canker sore relief, an over-the-counter ("OTC") product to treat oral ulcers and mouth sores; and NEXABAND® topical adhesives used in veterinary wound closure and wound care. In addition to its currently marketed products, CLOSURE's LIQUIDERM™ liquid adhesive bandage is the first and only cyanoacrylate medical device approved by the FDA for the OTC adhesive bandage market. CLOSURE has entered into a definitive agreement providing Johnson & Johnson Consumer Products Company with supply, distribution and development rights to its LIQUIDERM™ adhesive with the product launch expected to occur in early 2002. CLOSURE is also developing internal adhesives for wound closure and the possible treatment of emphysema, as well as developing liquid occlusive dressings for the treatment of a variety of partial thickness wounds, including pressure ulcers and skin tears.


DERMABOND adhesive is a registered trademark of Ethicon, Inc.; SOOTHE-N- SEAL™ is a licensed trademark of Colgate Oral Pharmaceuticals, Inc.; LIQUIDERM™ is a trademark of CLOSURE Medical Corporation; and NEXABAND® is a registered trademark of CLOSURE Medical Corporation.


To receive CLOSURE's latest news release and other corporate documents via fax, at no cost, call 1-800-PRO-INFO, use the Company's symbol CLSR. Or visit the Financial Relations Board's website at


This release contains certain forward-looking statements which involve known and unknown risks, delays, uncertainties or other factors not under the Company's control which may cause actual results, performance or achievements of the Company to be materially different from the results, performance, or other expectations implied by these forward-looking statements. These factors include, but are not limited to the early stage of commercialization of the Company products; the progress of its research and development programs for future products; the need for regulatory approval and effects of governmental regulation; technological uncertainties; the satisfactory conclusion of negotiations with, and dependence on marketing partners, and dependence on patents and trade secrets, as well as those detailed in the Company's Annual Report on Form 10-K for the year ended December 31, 2000 filed with the Securities and Exchange Commission.